Rhythm Pharmaceuticals, Inc. Share Price & Technical Analysis
RYTM · $87.84 (-2.61%)
Healthcare / Biotechnology
$87.84
-2.61%
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, B…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
7% return in May, -11% avg return in past 3 year May month.
-17% return in 2026, 58% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | -9% | -4% | -7% | 7% | – | – | – | – | – | – | – | -17% |
| 25 | 4% | -6% | -4% | 22% | -5% | 2% | 35% | 21% | -2% | 14% | -3% | -2% | 76% |
| 24 | -2% | -3% | 1% | -6% | -10% | 13% | 18% | -2% | 12% | -9% | 29% | -10% | 32% |
| 23 | -7% | -11% | -27% | 13% | -17% | 0% | 8% | 37% | -13% | 1% | 45% | 37% | 65% |
| 22 | -26% | 3% | 46% | -45% | -45% | 20% | 207% | 82% | 10% | 0% | 2% | 9% | 262% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.14B
P/E ratio
—
52W high
$122.2
52W low
$58.72
Volume
4,79,070
Beta
1.94
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Rhythm Pharmaceuticals, Inc. share price today?
- Rhythm Pharmaceuticals, Inc. (RYTM) last traded around $87.84 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RYTM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RYTM. Download the app for real-time alerts.
- How can I analyze Rhythm Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.